AstraZeneca has received approval from the European Commission (EC) to use its cancer drug, Tagrisso (osimertinib), in combination with pemetrexed and platinum-based chemotherapy as a first-line treatment for adult patients with advanced epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). This approval is specifically for patients whose tumors exhibit exon 19 deletions or […]
Maverix Medical, a leading lung cancer platform supported by Ajax Health, KKR, and Hologic, Inc., has officially announced its acquisition of Cirrus Bio, a company specializing in multiomic solutions for disease diagnosis and management, for an undisclosed sum. This strategic acquisition underscores Maverix Medical’s commitment to enhancing lung cancer diagnosis and treatment through advanced technological […]
Roche’s subsidiary, Genentech, has announced a significant breakthrough with the US Food and Drug Administration (FDA) approval of Tecentriq (atezolizumab). This new approval marks a pivotal development in the fight against extensive stage small cell lung cancer (ES-SCLC), as the monoclonal antibody will now be used in combination with chemotherapy as a first-line treatment for […]
Pfizer Inc., a leading US pharmaceutical company, has secured approval from the US Food and Drug Administration (FDA) for Lorbrena (lorlatinib), a groundbreaking treatment for anaplastic lymphoma kinase (ALK) positive metastatic non-small cell lung cancer (NSCLC). This approval marks a significant milestone in the fight against a challenging form of cancer, particularly for patients whose […]
Merck’s cancer immunotherapy Keytruda (pembrolizumab) in combination with chemotherapy has been approved by the US Food and Drug Administration (FDA) as a first-line option for advanced lung cancer treatment in patients who didn’t take any medicines before for the disease.
The US Food and Drug Administration (FDA) has granted approval to Merck’s cancer immunotherapy, Keytruda (pembrolizumab), in combination with chemotherapy, as a first-line treatment option for patients with advanced lung cancer who have not previously been treated with other medicines. This approval marks a pivotal development in the battle against metastatic non-squamous non-small cell lung […]
Swiss pharma Novartis has announced that its lung cancer drug Zykadia (ceritinib) has been granted the FDA priority review for its expanded use as the first-line treatment for lung cancer patients with certain conditions.
Novartis AG, a prominent Swiss pharmaceutical company, has received a significant regulatory boost as its lung cancer medication, Zykadia (ceritinib), has been granted a priority review by the U.S. Food and Drug Administration (FDA) for its expanded use in treating lung cancer. This priority review specifically targets its application as a first-line treatment for patients […]
Texas-based biopharmaceutical company Genprex has unveiled positive interim data from an ongoing phase II clinical trial, NCT01455389, for its lung cancer drug candidate, Oncoprex. Conducted at The University of Texas MD Anderson Cancer Center, the trial focuses on the investigational immunogene therapy drug in combination with the tyrosine kinase inhibitor erlotinib (Tarceva), targeting patients with […]